Cardiocast

New LDL-lowering drug under FDA review


 

This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.
Amazon Alexa
Apple Podcasts
Google Podcasts
TuneIn

Recommended Reading

Adult diabetes up 35% over 25 years
Federal Practitioner
Over 45% of American adults have type 2 diabetes mellitus or prediabetes
Federal Practitioner
Data support revising ASCVD cardiovascular risk threshold
Federal Practitioner
People with HIV still at increased cardiovascular risk
Federal Practitioner
‘Simple’ way to cut PAD risk, misguided ED visits for atrial fib, and more
Federal Practitioner
Statin adherence lower in women, minorities
Federal Practitioner
Hormone therapy in transgender individuals may up risk of CV events
Federal Practitioner
Who is least adherent to statins, and more
Federal Practitioner